Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment

Next Previous
X
Search
Trial Profile

Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Nov 2019 Results evaluating the efficacy of adding lapatinib to vinorelbine in patients who experienced disease progression after lapatinib and trastuzumab treatmentpublished in the British Journal of Cancer
    • 08 Dec 2018 Status changed from recruiting to completed, as reported in an abstract presented at the 41st Annual San Antonio Breast Cancer Symposium
    • 27 Dec 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top